GoldenGolden
Advanced Search
Soligenix

Soligenix

Soligenix is a Princeton, New Jersey-based developer of biodefense vaccines and therapeutics for the side-effects of cancer treatment and gastrointestinal diseases.

Soligenix, Inc. is a biotechnology company that focuses on the development and commercialization of products for treating rare diseases and addressing unmet medical needs.

Soligenix works on improving the lives of patients globally. Its leaders have many years of experience in the biopharmaceutical industry and expertise in developing rare disease therapies.

Soligenix specializes in developing orphan and unmet medical need indications that include preclinical, manufacturing, regulatory and clinical expertise. Soligenix is building SGX301 as a photo-dynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, SGX942, a novel innate defense regulator technology for the treatment of oral mucositis and SGX203, a proprietary formulations of oral beclomethasone 17, 21-dipropionate (BDP) for the prevention and treatment of gastrointestinal disorders that are characterized by severe inflammation including pediatric Crohn’s disease.

Soligenix offers public health solutions business segment that includes active development programs for RiVax®, its ricin toxin vaccine candidate, SGX943.

Timeline

May 3, 2013
Soligenix raises a $1,500,000 seed round.
1987
Soligenix was founded by Christopher J. Schaber.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Soligenix, Inc.
June 22, 2021
www.prnewswire.com:443
/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
Research and Markets
June 17, 2021
www.prnewswire.com:443
/PRNewswire/ -- The "Mycosis Fungoides Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies...
Soligenix, Inc.
June 10, 2021
www.prnewswire.com:443
/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
Soligenix, Inc.
June 9, 2021
www.prnewswire.com:443
/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
BioSpace
May 20, 2021
BioSpace
Soligenix, Inc. (Nasdaq: SNGX) announced today that the Japan Patent Office has allowed the patent application titled "Systems and Methods for Producing Synthetic Hypericin".
Soligenix, Inc.
May 20, 2021
www.prnewswire.com:443
/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
Soligenix, Inc.
May 17, 2021
www.prnewswire.com:443
/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
Soligenix, Inc.
May 10, 2021
www.prnewswire.com:443
/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
BioSpace
May 4, 2021
BioSpace
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Ellen Kim , MD, Medical Director, Dermatology Clinic, Perelman Center for Advanced Medicine presented data at the Society for Investigative Dermatology
Soligenix, Inc.
April 28, 2021
www.prnewswire.com:443
/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
BioSpace
April 26, 2021
BioSpace
Soligenix, Inc. products to treat rare diseases where there is an unmet medical need, announced today that Ellen Kim , MD, Medical Director, Dermatology Clinic, delivered a presentation at the American Academy of Dermatology (AAD) Association Virtual Meeting Experience, held April 23-25, 2021.
Soligenix, Inc.
April 26, 2021
www.prnewswire.com:443
/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
Soligenix, Inc.
February 11, 2021
www.prnewswire.com:443
/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
Soligenix
February 1, 2021
www.prnewswire.com:443
/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
Soligenix, Inc.
January 19, 2021
www.prnewswire.com:443
/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
Soligenix, Inc.
December 28, 2020
www.prnewswire.com:443
/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
Soligenix, Inc.
December 22, 2020
www.prnewswire.com:443
/PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
Soligenix, Inc.
December 8, 2020
www.prnewswire.com:443
/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
Soligenix, Inc.
September 16, 2019
www.prnewswire.com:443
PRINCETON, N.J., Sept. 16, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.